Haemonetics Corporation 10-Q Summary
Business Context and Reporting Period
Company: Haemonetics Corporation
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 26, 2009 (Second Quarter of Fiscal Year 2010)
Business Overview: Haemonetics designs, manufactures, and markets automated blood processing systems, including plasma and blood bank systems, surgical disposables, and software solutions for blood management. The company operates globally with approximately 52% of revenues generated outside the U.S.
Key Financial Metrics
| Metric (in thousands) | Q2 2009 | Q2 2008 | 6 Months 2009 | 6 Months 2008 |
|---|---|---|---|---|
| Net Revenues | $157,070 | $145,919 | $311,158 | $290,035 |
| Gross Profit | $80,967 | $74,689 | $163,910 | $147,726 |
| Gross Margin | 51.5% | 51.2% | 52.7% | 50.9% |
| Operating Income | $27,023 | $23,609 | $53,350 | $42,943 |
| Net Income | $18,050 | $14,807 | $36,123 | $29,148 |
| Diluted EPS | $0.69 | $0.57 | $1.37 | $1.11 |
| Cash & Equivalents | $178,322 (as of Sept 26, 2009) | |||
| Working Capital | $293,302 (as of Sept 26, 2009) | |||
| Net Cash Position | $158,167 (as of Sept 26, 2009) |
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased 7.6% in Q2 and 7.3% for the six months ended Sept 26, 2009, compared to the prior year. Growth was driven by a 19.0% increase in plasma disposables and a 28.5% increase in software solutions revenue. Foreign exchange contributed approximately 2.1% to Q2 revenue growth.
- Profitability: Operating income increased 14.5% in Q2 and 24.2% for the six-month period. Net income rose 21.9% in Q2 and 23.9% for the six months. Gross margins improved due to manufacturing efficiencies and favorable foreign exchange, partially offset by a shift toward lower-margin plasma products.
- Acquisitions: The company completed two significant acquisitions in the first six months of FY2010: SEBRA (blood collection assets) for $12.8 million and Neoteric (medical information management) for $6.7 million plus contingent consideration. These contributed to revenue growth and increased operating expenses.
- Expense Trends: Operating expenses increased 5.6% in Q2, primarily due to higher R&D spending (up 24.1%), costs associated with recent acquisitions, and ERP Phase II implementation. Restructuring costs were absent in the current period, unlike the prior year.
Guidance, Outlook, and Risks
- Outlook: Management anticipates plasma disposable revenue growth will moderate but continue to outpace collection market growth (estimated at 7%) due to price increases and market share gains. The company expects to enter the automated whole blood collection market in early 2011.
- Foreign Exchange: Approximately 52% of sales are in foreign currencies (primarily Euro and Yen). A strengthening U.S. dollar negatively impacts results, while a weakening dollar provides a benefit. The company uses forward contracts to hedge anticipated cash flows.
- Legal Proceedings: In a patent infringement lawsuit against Fenwal (formerly Baxter), a jury awarded Haemonetics $15.7 million in damages. An amended judgment in August 2009 increased the total award to $18.0 million, including lost profits, royalties, and interest. Fenwal is enjoined from selling ALYX consumables after December 1, 2010. Appeals are possible.
- Capital Allocation: The Board approved a $40 million share repurchase program in May 2009. As of Sept 26, 2009, $7.6 million had been spent, with $32.4 million remaining.
- Risks: Key risks include foreign currency volatility, regulatory uncertainties, dependence on the plasma market, and the impact of macroeconomic conditions on healthcare funding.
Investor Verification Checklist
- Acquisition Integration: Verify the financial contribution and integration progress of the SEBRA and Neoteric acquisitions.
- Plasma Market Dynamics: Monitor the balance between plasma supply and demand, as well as pricing trends in the pharmaceutical sector.
- Legal Resolution: Track the status of the Fenwal patent litigation appeal and the potential collection of the $18.0 million award.
- Foreign Exchange Exposure: Assess the impact of currency fluctuations on future earnings, given the 52% international revenue mix.
- Product Pipeline: Confirm the timeline for the launch of the next-generation Blood Bank apheresis platform and the automated whole blood collection system.